Charles Schwab’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.3M Sell
924,039
-41,853
-4% -$694K ﹤0.01% 1925
2025
Q4
$18.3M Buy
965,892
+101,512
+12% +$1.46M ﹤0.01% 1803
2025
Q3
$7.99M Buy
864,380
+257,253
+42% +$2.67M ﹤0.01% 2212
2025
Q2
$6.92M Buy
607,127
+25,061
+4% +$271K ﹤0.01% 2186
2025
Q1
$6.91M Buy
582,066
+9,232
+2% +$154K ﹤0.01% 2130
2024
Q4
$10.8M Buy
572,834
+61,114
+12% +$1.4M ﹤0.01% 1984
2024
Q3
$11.5M Sell
511,720
-111,684
-18% -$2.53M ﹤0.01% 1960
2024
Q2
$13M Sell
623,404
-18,786
-3% -$293K ﹤0.01% 1908
2024
Q1
$9.44M Buy
642,190
+19,893
+3% +$214K ﹤0.01% 2015
2023
Q4
$6.42M Buy
622,297
+53,721
+9% +$368K ﹤0.01% 2203
2023
Q3
$4.47M Buy
568,576
+184,617
+48% +$1.69M ﹤0.01% 2309
2023
Q2
$3.84M Sell
383,959
-881
-0.2% -$8.98K ﹤0.01% 2339
2023
Q1
$3.42M Buy
384,840
+1,925
+0.5% +$20.1K ﹤0.01% 2367
2022
Q4
$4.2M Buy
382,915
+8,342
+2% +$101K ﹤0.01% 2306
2022
Q3
$4.88M Buy
374,573
+84,114
+29% +$1.33M ﹤0.01% 2226
2022
Q2
$3.68M Buy
290,459
+20,404
+8% +$231K ﹤0.01% 2317
2022
Q1
$3.78M Buy
270,055
+6,415
+2% +$114K ﹤0.01% 2406
2021
Q4
$7.63M Buy
263,640
+3,880
+1% +$118K ﹤0.01% 2140
2021
Q3
$7.78M Buy
259,760
+129,872
+100% +$4.01M ﹤0.01% 2153
2021
Q2
$3.45M Buy
129,888
+16,953
+15% +$498K ﹤0.01% 2531
2021
Q1
$3.51M Buy
112,935
+36,064
+47% +$1.36M ﹤0.01% 2459
2020
Q4
$2.53M Buy
76,871
+4,662
+6% +$154K ﹤0.01% 2532
2020
Q3
$2.52M Buy
+72,209
New +$1.82M ﹤0.01% 2417

Other funds holding NRIX